Evelin Jadán

Ms. Evelin Jadán

orcid
Biochemistry and Pharmacy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
GCGénesis Cartagena
Génesis Cartagena
Evelin JadánEvelin Jadán
Evelin Jadán
Juan Diego GuarimataJuan Diego Guarimata
Juan Diego Guarimata
The Aurora kinase A (Aurora-A), overexpressed in cancer cells, represents a promising anti-cancer therapeutic target due to its role in mitotic progression and chromosome instability. Aurora-A contains a recently described drug pocket within its Targeting Protein for Xklp2 (TPX2) interaction site, offering a promising target for small-molecule disruption and selective inhibition. In this study, 1281 natural products from Argentina’s database (NaturAr), encompassing chemically diverse and structurally rich metabolites, were evaluated using a machine learning model based on molecular fingerprints and variational autoencoders (VAEs) to predict inhibitory activity with high-throughput efficiency. From this initial screening, 624 compounds were classified as active type against Aurora-A, and subsequently subjected to molecular docking using FRED software (v4.3.0.3) against the Aurora-A crystal structure (PDB: 5OSD), focusing on the TPX2-binding interface. Among them, 117 compounds with various scaffolds showed better binding scores than the co-crystallized ligand, highlighting their potential to interact with the druggable target site through stable and specific molecular contacts. This workflow effectively prioritized compounds of natural origin from Argentina for the discovery of new Aurora-A kinase inhibitors, demonstrating the value of integrating AI-driven screening with structure-based modeling. These findings highlight the identification of novel scaffolds with high binding potential, offering promising starting points for the development of selective Aurora-A inhibitors.

13 November 2025 in Chemistry Proceedings
Verified
Conference Paper
Open access
PDF file
Evelin JadánEvelin Jadán
Evelin Jadán
Juan Diego GuarimataJuan Diego Guarimata
Juan Diego Guarimata
Javier SantamaríaJavier Santamaría
Javier Santamaría
Antimicrobial resistance represents a mounting global health concern, primarily attributable to the widespread and indiscriminate use of antibiotics. This has led to the emergence of resistant strains and a gradual decline in the clinical efficacy of existing therapeutic agents. In this context, the design of new antimicrobials remains a significant challenge. This study evaluated, using in silico tools, the binding affinity of eight novel fluoroquinolone derivatives against the DNA gyrase of six bacterial species, using moxifloxacin as the reference compound. Target protein sequences were retrieved from the Protein Data Bank and GenBank and subsequently modeled using SwissModel, I-TASSER, and Phyre2. The generated structures were assessed with MolProbity, and those with the best scores were selected for molecular docking. Proteins were prepared using Chimera 1.18 and AutoDockTools 1.5.7. The active site was identified with Discovery Studio 2024. Ligands were built in ZINC, prepared using Open Babel v3.1.1.60, and docked with AutoDock Vina v1.2.3.57. Docking validation was performed with DockRMSD. Considering these results, four new molecules (A1, B1, C1, and D2) were designed to improve their pharmacokinetic properties by modifying the TPSA value of the original structures. However, the new docking assays revealed that these optimized compounds did not exhibit a significant increase in affinity toward the target enzyme. The findings suggest that compound C retains a favorable profile as a potential antimicrobial agent against resistant strains.